Cingulate (NASDAQ:CING – Get Free Report) is expected to release its earnings data before the market opens on Monday, March 24th. Analysts expect Cingulate to post earnings of ($1.48) per share for the quarter.
Cingulate Trading Down 3.2 %
Shares of CING opened at $3.96 on Friday. Cingulate has a fifty-two week low of $1.80 and a fifty-two week high of $20.83. The firm has a 50-day simple moving average of $4.34 and a 200-day simple moving average of $4.55.
Wall Street Analysts Forecast Growth
CING has been the subject of a number of recent analyst reports. Roth Mkm initiated coverage on shares of Cingulate in a research report on Friday, January 10th. They issued a “buy” rating and a $12.00 price objective for the company. Roth Capital upgraded shares of Cingulate to a “strong-buy” rating in a research report on Friday, January 10th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Cingulate in a research report on Thursday, March 6th.
About Cingulate
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
Featured Stories
- Five stocks we like better than Cingulate
- How to Calculate Options Profits
- FedEx Delivers Another Crushing Blow to Its Stock Price
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- ETF Screener: Uses and Step-by-Step Guide
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.